PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for PTC Therapeutics, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Financial Expectations - PTC Therapeutics is expected to report a quarterly loss of $0.21 per share, reflecting a year-over-year change of +12.5% [3]. - Revenues are projected to be $304.72 million, representing a 43% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 15.33% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for PTC Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +133.56% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - PTC Therapeutics has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, PTC Therapeutics was expected to post a loss of $1.19 per share but instead reported earnings of $0.20, achieving a surprise of +116.81% [13]. - The company has beaten consensus EPS estimates in each of the last four quarters [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, BioMarin Pharmaceutical is expected to post earnings of $0.25 per share, indicating a year-over-year change of -72.8% [18]. - BioMarin's revenue is expected to be $829.66 million, up 11% from the previous year, but the consensus EPS estimate has been revised 1.2% lower [19].